Your browser doesn't support javascript.
loading
Inter-center comparison of good manufacturing practices-compliant stromal vascular fraction and proposal for release acceptance criteria: a review of 364 productions.
François, Pauline; Rusconi, Giulio; Arnaud, Laurent; Mariotta, Luca; Giraudo, Laurent; Minonzio, Greta; Veran, Julie; Bertrand, Baptiste; Dumoulin, Chloé; Grimaud, Fanny; Lyonnet, Luc; Casanova, Dominique; Giverne, Camille; Cras, Audrey; Magalon, Guy; Dignat-George, Françoise; Sabatier, Florence; Magalon, Jeremy; Soldati, Gianni.
Afiliação
  • François P; Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, 147 Bd Baille, 13005, Marseille, France.
  • Rusconi G; Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France.
  • Arnaud L; Swiss Stem Cell Foundation, Gentilino, Lugano, Switzerland.
  • Mariotta L; Department of Biotechnology and Life Sciences, University of Insubria, Varese, Italy.
  • Giraudo L; Vascular Biology Department, Hôpital de la Conception, AP-HM, Marseille, France.
  • Minonzio G; Swiss Stem Cell Foundation, Gentilino, Lugano, Switzerland.
  • Veran J; Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, 147 Bd Baille, 13005, Marseille, France.
  • Bertrand B; Swiss Stem Cell Foundation, Gentilino, Lugano, Switzerland.
  • Dumoulin C; Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, 147 Bd Baille, 13005, Marseille, France.
  • Grimaud F; Plastic Surgery Department, Hôpital de la Conception, AP-HM, Marseille, France.
  • Lyonnet L; Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, 147 Bd Baille, 13005, Marseille, France.
  • Casanova D; Cell Therapy Department, Hôpital de la Conception, AP-HM, INSERM CIC BT 1409, 147 Bd Baille, 13005, Marseille, France.
  • Giverne C; Vascular Biology Department, Hôpital de la Conception, AP-HM, Marseille, France.
  • Cras A; Plastic Surgery Department, Hôpital de la Conception, AP-HM, Marseille, France.
  • Magalon G; Normandie Univ, UNIROUEN, INSERM, U1234, Rouen University Hospital, Department of Immunology and Biotherapy, Rouen, France.
  • Dignat-George F; Assistance Publique-Hôpitaux de Paris, Saint-Louis Hospital, Cell Therapy Unit, Cord blood Bank and CIC-BT501, Paris, France.
  • Sabatier F; Remedex, Marseille, France.
  • Magalon J; Aix Marseille Univ, INSERM, INRA, C2VN, Marseille, France.
  • Soldati G; Vascular Biology Department, Hôpital de la Conception, AP-HM, Marseille, France.
Stem Cell Res Ther ; 12(1): 373, 2021 07 01.
Article em En | MEDLINE | ID: mdl-34210363
ABSTRACT

BACKGROUND:

Even though the manufacturing processes of the stromal vascular fraction for clinical use are performed in compliance with the good manufacturing practices applying to advanced therapy medicinal products, specifications related to stromal vascular fraction quality remain poorly defined. We analyzed stromal vascular fraction clinical batches from two independent good manufacturing practices-compliant manufacturing facilities, the Swiss Stem Cell Foundation (SSCF) and Marseille University Hospitals (AP-HM), with the goal of defining appropriate and harmonized release acceptance criteria.

METHODS:

This retrospective analysis reviewed the biological characteristics of 364 batches of clinical-grade stromal vascular fraction. Collected data included cell viability, recovery yield, cell subset distribution of stromal vascular fraction, and microbiological quality.

RESULTS:

Stromal vascular fraction from SSCF cohort demonstrated a higher viability (89.33% ± 4.30%) and recovery yield (2.54 × 105 ± 1.22 × 105 viable nucleated cells (VNCs) per mL of adipose tissue) than stromal vascular fraction from AP-HM (84.20% ± 5.96% and 2.25 × 105 ± 1.11 × 105 VNCs per mL). AP-HM batches were significantly less contaminated (95.71% of sterile batches versus 74.15% for SSCF batches). The cell subset distribution was significantly different (higher proportion of endothelial cells and lower proportion of leukocytes and pericytes in SSCF cohort).

CONCLUSIONS:

Both centers agreed that a good manufacturing practices-compliant stromal vascular fraction batch should exert a viability equal or superior to 80%, a minimum recovery yield of 1.50 × 105 VNCs per mL of adipose tissue, a proportion of adipose-derived stromal cells at least equal to 20%, and a proportion of leukocytes under 50%. In addition, a multiparameter gating strategy for stromal vascular fraction analysis is proposed.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tecido Adiposo / Células Endoteliais Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Tecido Adiposo / Células Endoteliais Idioma: En Ano de publicação: 2021 Tipo de documento: Article